Pharmacological and biochemical characterization of bradykinin B2 receptors in the mouse colon: influence of the TNBS-induced colitis.
This study analyzed bradykinin (BK)-evoked contractile responses in the mouse colon under normal and inflammatory conditions. BK and the preferential B(2) receptor agonists Hyp(3)-BK, Lys-BK, Met-Lys-BK and Tyr(8)-BK produced a marked and concentration-related contraction of the normal mouse colon, whereas the selective B(1) receptor agonist des-Arg(9)-BK had no effect. BK-induced contraction was concentration-dependently antagonized (in a non-competitive manner) by both B(2) receptor antagonists Hoe 140 and FR173657, but not the B(1) receptor antagonist des-Arg(9)-[Leu(8)]-BK. Analysis of the possible mechanisms implicated in the contractile responses of BK in the mouse colon revealed the involvement of the neural release of acetylcholine, the activation of L- and N-type voltage-gated calcium channels, and the release of neuropeptides, prostanoids and leukotrienes. The contraction induced by BK was markedly increased in preparations obtained from TNBS-treated mice. The up-regulation of B(2) receptors following the induction of colitis was confirmed with binding studies using [(3)H]-BK, which revealed a marked increase in B(2) receptor densities, without alterations of affinity. We provide convincing evidence on the relevance of B(2) receptors in the mouse colon under normal conditions, as well as under an inflammatory profile of colitis. Selective B(2) receptor antagonists might well represent rational therapeutic options for treating inflammatory bowel diseases.
Hara
Daniela Balz
DB
Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil.
Fernandes
Elizabeth Soares
ES
Campos
Maria Martha
MM
Calixto
João B
JB
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D065094:Bradykinin B2 Receptor Antagonists; D020746:Calcium Channels, L-Type / Q000378:metabolism; D020864:Calcium Channels, N-Type / Q000378:metabolism; D003092:Colitis / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology*; D003106:Colon / Q000378:metabolism / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D007609:Kallidin / Q000494:pharmacology; D015289:Leukotrienes / Q000378:metabolism; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects*; D009479:Neuropeptides / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism; D011804:Quinolines / Q000494:pharmacology; D043782:Receptor, Bradykinin B2 / Q000819:agonists / Q000737:chemistry*; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity
D065094:Bradykinin B2 Receptor Antagonists; D020746:Calcium Channels, L-Type; D020864:Calcium Channels, N-Type; C105311:FR 173657; D015289:Leukotrienes; D009479:Neuropeptides; D011453:Prostaglandins; D011804:Quinolines; D043782:Receptor, Bradykinin B2; D007609:Kallidin; C065679:icatibant; D014302:Trinitrobenzenesulfonic Acid; D000109:Acetylcholine; D001920:Bradykinin